New Review Highlights Calciphylaxis in Kidney Diseases
Patients with calciphylaxis benefit from multidisciplinary care including nephrology, dermatology, and palliative care, according to a new review.
Patients with calciphylaxis benefit from multidisciplinary care including nephrology, dermatology, and palliative care, according to a new review.
No medication is currently approved to treat vascular calcification in this population.
Author reviews calciphylaxis incidence, risk factors, pathogenesis, differential diagnoses, and treatment.
Take the quiz on this clinical case: Which of the following is NOT associated with non-uremic calciphylaxis?
Calciphylaxis treatment should include a multimodal approach with a focus on supportive care, infection prevention, pain management, and wound healing.
In a case-control study, unintentional weight loss within 6 months emerged as a new calciphylaxis risk factor in hemodialysis patients.
First-ever randomized controlled trial of a treatment for calciphylaxis demonstrated improvements in survival, pain, and lesion size.
In a small study, vitamin K antagonist use and liver dysfunction emerged as the most important factors in the development of calciphylaxis.
In patients with stage 5 chronic kidney disease, lupus anticoagulant and combined thrombophilia occur more frequently in those with versus without calciphylaxis, case-control study shows.
A patient experienced painful skin ulcers despite having normal renal function.